← Return to ARPI use after radiation treatment may be an issue

Discussion
Jeff Marchi avatar

ARPI use after radiation treatment may be an issue

Prostate Cancer | Last Active: 14 hours ago | Replies (41)
Comment receiving replies
Profile picture for Jeff Marchi @jeffmarc

@northoftheborder
Bayer sued Johnson and Johnson over its claims that Erleada patients with CSPC lived longer than those that took Nubeqa.

Bayer Claims the study was biased.

Available comparative data indicates that Nubeqa generally has a more favorable safety profile, particularly regarding fatigue, falls, and rash.
Journal of Hematology Oncology Pharmacy

Lots of differences of opinion.

Jump to this post

Replies to "@northoftheborder Bayer sued Johnson and Johnson over its claims that Erleada patients with CSPC lived longer..."
northoftheborder | @northoftheborder | 15 hours ago

@jeffmarc Yes, I know that Bayer sued to get ahead of the news cycle (probably a good move, since J&J's study was a little hastily-assembled).

Still, while I know that Bayer predicts fewer side-effects, based on Darolutamide being less likely to cross the blood/brain barrier in-vitro, I haven't (yet) seen a head-to-head trial with other -lutamides establishing that the theory pans out for humans (just retrospective comparisons across different trials done at different times for other purposes with varying methodologies, much as J&J did with their iffy study).

VIEW AND REPLY